Skip to main content

Dual-stage cognitive assessment: a two-stage screening for cognitive impairment in primary care



Aging population has led to an increased proportion of older adults and cognitively impaired. We designed a brief and flexible two-stage cognitive screening scale, the Dual-Stage Cognitive Assessment (DuCA), for cognitive screening in primary care settings.


In total, 1,772 community-dwelling participants were recruited, including those with normal cognition (NC, n = 1,008), mild cognitive impairment (MCI, n = 633), and Alzheimer’s disease (AD, n = 131), and administered a neuropsychological test battery and the DuCA. To improve performance, the DuCA combines visual and auditory memory tests for an enhanced memory function test.


The correlation coefficient between DuCA-part 1 and DuCA-total was 0.84 (P < 0.001). The correlation coefficients of DuCA-part 1 with Addenbrooke’s Cognitive Examination III (ACE-III) and Montreal Cognitive Assessment Basic (MoCA-B) were 0.66 (P < 0.001) and 0.85 (P < 0.001), respectively. The correlation coefficients of DuCA-total with ACE-III and MoCA-B were 0.78 (P < 0.001) and 0.83 (P < 0.001), respectively. DuCA-Part 1 showed a similar discrimination ability for MCI from NC (area under curve [AUC] = 0.87, 95%CI 0.848–0.883) as ACE III (AUC = 0.86, 95%CI 0.838–0.874) and MoCA-B (AUC = 0.85, 95%CI 0.830–0.868). DuCA-total had a higher AUC (0.93, 95%CI: 0.917–0.942). At different education levels, the AUC was 0.83–0.84 for DuCA-part 1, and 0.89–0.94 for DuCA-total. DuCA-part 1 and DuCA-total’s ability to discriminate AD from MCI was 0.84 and 0.93, respectively.


DuCA-Part 1 would aid rapid screening and supplemented with the second part for a complete assessment. DuCA is suited for large-scale cognitive screening in primary care, saving time and eliminating the need for extensively training assessors.

Peer Review reports


The accelerated aging of the Chinese population is posing a public health challenge [1]. Currently, approximately 15 million people aged > 60 years have dementia in China [2]. Dementia causes tremendous suffering in patients and substantial economic burden for society. To address this challenge, screening for mild cognitive impairment (MCI) must be prioritized and promoted. Establishing health records of the 260 million older adults in China will help identify patients with cognitive impairment. However, primary care resources in China are inadequate. In China, raters are not considered professionals, and no registration system exists. Therefore, the number of raters with neuropsychological training is insufficient.

There are many approaches to identifying dementia, either from informants [3], such as using the Alzheimer’s disease 8 (AD8) [4] and the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) [5] or from daily life observations, such as the Activity of Daily Living (ADL) scale [6]. Cognitive screening measures for dementia such as the Mini-Mental State Examination (MMSE) [7], Montreal Cognitive Assessment (MoCA) [8], and Clock Drawing Test (CDT) [9] are commonly used.

The overall prevalence of MCI in China is estimated to be 15.5% [2]. Large-scale rapid screening of community residents by primary care providers (e.g., family physicians) is a practical approach to improve the diagnosis and management of cognitive impairment in such a huge population. Therefore, appropriate cognitive-screening scales are required. However, the current Chinese versions of these screening scales have limitations for screening MCI. In the Chinese version of these screening scales, memory assessment comprises of only one item. The memory assessment component of Memory and Executive Screening (MES) [10] is the auditory memory of a sentence with 10 key points, while that of the Hong Kong Brief Cognitive Test (HKBC) [11] is auditory memory of four objects. The memory assessment component of the Five-Minute Cognitive Test [12] is visual memory of eight objects. The Geriatric Cognitive Comprehensive Assessment Examiner-Rating Scale (GCCAES) [13] examines three-word auditory memory similar to the MMSE. However, these four screening scales do not fully reflect memory function. Except for the MES, the difficulty of the memory items is lower than that of the MoCA.

The MoCA is one of the most commonly used screening scales; however, it is highly time-consuming and unsuitable for amnestic MCI screening. The MoCA has only five points for memory items (25/30 points on the MoCA are not situational episodic memory items), and some items are not sensitive enough for screening MCI, such as 100 consecutive minus seven and digit spans. Another commonly used scale, the MMSE, has similar issues regarding memory function evaluation.

Therefore, identifying MCI quickly and accurately in the Chinese cultural background requires the development of new, rapid, and practical tools. Hence, we conceived a two-stage process. The first part of the instrument was designed to be very short, taking approximately three minutes to complete, and providing good sensitivity and acceptable specificity. This process was intended to exclude those with good cognitive function and those with poor cognitive function in the community, to save assessor resources. The former does not require further assessment, whereas the latter requires direct referral to a specialized facility for a detailed assessment and specialist examination. It is worth clarifying that cognitive impairment may involve impairment in multiple cognitive domains, and even cognitive impairment due to AD may have an atypical presentation. Our design enhances the detection of memory functions rather than assess the full range of cognitive domains. This was done to allow lay assessors in primary care, usually in the community, to detect cognitive impairment due to typical AD within the shortest possible time. Individuals with suspected cognitive impairment detected using the first part should be assessed using the second part of the test. Therefore, the second part improves the specificity of the entire tool.

A final definitive diagnosis of cognitive impairment can only be made in hospitals or specialized facilities. It requires multiple assessments, biomarker testing, and precise diagnosis by a medical professional based on appropriate diagnostic criteria. Biomarkers such as β-amyloid are becoming increasingly prevalent in the diagnosis of AD [14]. Primary healthcare facilities usually do not have the necessary equipment or capacity to detect biological markers using positron emission tomography or cerebrospinal fluid analysis. If cognitive screening can help identify biomarkers, it can increase the ability for initially determining cognitive impairment pathology in primary care settings. We have added an assessment of prospective memory [15] and metamemory [16], which may be more sensitive or related to β-amyloid pathology, to this new assessment tool. We hope to validate their role in the identification of biomarkers in subsequent studies.

In summary, the huge community population in China needs to be screened for cognitive impairments; however, limited assessment resources are available. Therefore, a flexible, effective, and rapid assessment tool was required. This study aimed to develop a cognitive screening scale, the Dual-Stage Cognitive Assessment (DuCA), for cognitive function screening in primary care. The characteristics of the DuCA may enable the rapid screening of older adults with cognitive impairment in the community. To our knowledge, no similar two-stage screening tool has been used on a large scale in China. A novel assessment tool, such as DuCA, would aid large-scale cognitive screening in primary care.



The participants were recruited from a cognition clinic and the local community. All participants had to meet the following criteria: (1) native Chinese speakers; (2) no history of stroke, craniocerebral injury, brain tumor, anxiety or depression, or other systemic diseases that affect brain function; and (3) absence of severe hearing or visual impairment, enabling them to complete the neuropsychological test. Individuals with (1) a history of alcohol or drug abuse, psychiatric disorders, epilepsy, head trauma, stroke, or other severe neurological disorders; (2) significant thyroid function abnormalities or syphilis serology; and (3) dementia or MCI caused by known non-AD etiologies such as stroke, Parkinson’s disease, Lewy body dementia, or frontotemporal degeneration were excluded.

Neuropsychological tests and diagnostic criteria

Basic assessments were conducted for all participants, including the Mini-Mental State Examination (MMSE) [7], Montreal Cognitive Assessment Basic (MoCA-B) [8], Addenbrooke’s Cognitive Examination III (ACE III) [17], Subjective Cognitive Decline Interview (SCD-I) [18], Everyday Cognition (ECOG) [19], Functional Activity Questionnaire (FAQ) [20], and ADL [6].

MCI was diagnosed using the 2011 National Institute on Aging-Alzheimer’s Association (NIA-AA) 2011 criteria [21]. Diagnostic assessments were performed using the following neuropsychological tests: the Auditory Verbal Learning Test (AVLT) [22], Brief Visuospatial Memory Test-Revised (BVMT) [23], Animal Fluency Test (AFT) [24], Boston Naming Test (BNT) [25], Shape Trail Test (STT)-A, and STT-B [26]. An indicator with more than one standard deviation below the age-corrected mean indicates impairment [27].

AD was diagnosed using the NIA-AA 2011 diagnostic criteria for probable AD [28]. Specifically, the diagnostic criteria for AD met the criteria for dementia and had the following characteristics: (1) insidious onset; (2) clear-cut history of worsening of cognition by report or observation; and (3) initial and most prominent cognitive deficits manifested as amnestic presentation or the following non-amnestic presentations: language function impairment, visuospatial function impairment, or executive function impairment [28].


The DuCA was designed as a two-stage assessment of cognitive impairment. In the rapid screening stage, part 1 was used to screen for cognitive function within approximately 3 min. Part 2 was administered to people with suspected cognitive impairment and forms the final total score along with Part 1. Table S1 shows the complete contents of the DuCA. To thoroughly test the performance of the DuCA, all participants underwent the two-part assessment.

The total score for part 1 was 10 points. In Part 1, the items used to calculate the total score were verbal fluency (two points), visual perception (three points), and delayed recall (five points). Initially, the tester orally presented five words to the participants and asked them to remember and recall them immediately. Scores for immediate recall were not included in the total score; this step was intended as a preparation for delayed recall. The verbal fluency item required participants to name as many fruits as possible in 1 min. For visual perception item, the tester presented a picture of 10 objects with overlapping silhouettes and asked the participants to name these objects. For the delayed recall item, participants were asked to name five words that they remembered from the immediate recall item (Table S1 in the Supplement).

The total score for part 2 was 28 points. In Part 2, the items used to calculate the total score were auditory sentence memory (six points), category switching (10 points), and visual memory (12 points). Initially, the tester presented pictures of 12 objects and asked the participants to name them. After observing these pictures for 30 s, the participants were asked to perform an immediate recall. After observing the pictures again for 1 min, a second immediate recall was performed. Points for image naming and the first immediate recall were not included in the total score. For the auditory sentence memory item, the testers orally stated a sentence with three names and four address elements. Participants were then asked to repeat the sentence, and the correct elements were recorded. For the category-switching test item, the participants were requested to orally generate objects in the order of alternating animals and fruits within 60 s, such as dogs, apples, horses, oranges, mice, and bananas. Next, delayed visual memory recall was performed. The participants were asked to recall the objects in the 12 pictures. The visual memory score was the total score of the second immediate recall and delayed free recall, divided by two.

The total score obtained by adding these two scores was 38. The DuCA comprised additional items on prospective memory and metamemory. These items do not count toward the total score, but provided additional information. We plan to cover prospective memory and metamemory in future studies.


Data analysis was performed using SPSS (SPSS Inc., Chicago, IL, USA) and Jamovi ( software. Participants with missing diagnostic neuropsychological evaluations were excluded, as previously described. Potential confounders, including sex, age, and years of education, were compared between groups. Descriptive statistics for the DuCA used sex as the stratification factor. Categorical variables were presented using percentages, and quantitative data were presented as mean ± standard deviation (SD). Categorical data were analyzed using the Chi-square test. Quantitative data were analyzed using the t-test between two groups, effect size was reported, and multiple group comparisons were performed using one-way analysis of variance (One-way ANOVA). The Games-Howell test was used for post-hoc analyses. Correlations between neuropsychological test scores were estimated using Pearson’s correlation coefficients. Logistic regression analysis and the area under the curve (AUC) for receiver operating characteristic (ROC) analysis were used to describe the discriminative capabilities of the assessments. In the logistic regression analysis, years of education was used as a stratifying factor.


Demography and general neuropsychological performance

In total, 4,536 participants were screened between April 2019 and July 2022. Among these, 1,989 participants were excluded because they did not meet the inclusion criteria or met the exclusion criteria; further, 775 participants were excluded because of failure to complete the required neuropsychological test battery or DuCA. Eventually, 1,772 participants were included in the analysis (Fig. 1). The normal cognition (NC) group included 1,008 participants (359 men, aged 65.12 ± 6.99 years, education 12.21 ± 3.25 years). The MCI group included 633 participants (206 men, aged 66.14 ± 6.78 years, education 11.03 ± 3.21 years). The AD group included 131 participants (51 men, aged 71.99 ± 6.67 years, education 10.77 ± 3.72 years). The AD, MCI, and NC groups showed progressively higher scores on ECOG (27.58 ± 10.27, 19.30 ± 7.50, 17.25 ± 5.93, P < 0.001), ADL (22.89 ± 4.36, 20.53 ± 2.07, 20.30 ± 2.27, P < 0.001), FAQ (4.88 ± 5.22, 1.07 ± 2.51, 0.49 ± 1.76, P < 0.001), and progressively lower scores on ACE III (56.18 ± 7.18, 69.49 ± 8.24, 81.34 ± 7.15, P < 0.001), MoCA-B (14.86 ± 3.64, 21.07 ± 3.50, 25.60 ± 2.70, P < 0.001), MMSE (21.07 ± 2.08, 26.2 ± 2.21, 27.96 ± 1.73, P < 0.001) (Table 1).

Fig. 1
figure 1

Study flow chart

Table 1 Demographic and neuropsychological test information

Some participants in the NC group had subjective cognitive complaints. Some participants admitted that they had subjective cognitive complaints; those who presented to the cognitive clinic with subjective cognitive complaints were considered cognitively normal after neuropsychological testing. Thus, a relatively large proportion of the normative cohort had subjective cognitive complaints (n = 468; 46.4%). The underlying diseases in the NC group were as follows: 128 participants had coronary heart disease (12.7%), 355 had hypertension (35.2%), 203 had dyslipidemia (20.1%), 174 had diabetes (17.3%), and 193 had chronic respiratory disease (19.1%).

Performance of NC and MCI groups in diagnostic assessments

The MCI group obtained lower scores than the NC group in the memory domain, including AVLT immediate recall, AVLT short delay-free recall, AVLT long delay-free recall, AVLT long delay-cued recall, AVLT recognition, BVMT immediate recall, BVMT short delay-free recall, BVMT long delay-free recall, and BVMT recognition (P < 0.001). The MCI group also obtained lower scores than the NC group in the language domain, including the BNT and VFT, and in the execution domain, including the STT-A and STT-B (P < 0.001) (Table 2).

Table 2 Comparison of diagnostic neuropsychological tests between NC group and MCI group

Psychometric properties of DuCA

The NC, MCI, and AD groups had decreasing scores in DuCA-part 1 (6.95 ± 1.70, 4.37 ± 1.75, 2.24 ± 1.09, respectively, P < 0.001) and DuCA-total (26.46 ± 4.01, 18.41 ± 3.90, 10.13 ± 2.92, respectively, P < 0.001). We also analyzed whether sex affected DuCA scores. The results showed no differences in DuCA scores, including part 1 and total scores, between men and women (Table 1).

The correlation coefficient between DuCA-part 1 and DuCA-total was 0.84 (P < 0.001). The standardized Cronbach’s coefficient was 0.56 for the first part of the DuCA and 0.78 DuCA total. The inter-rater reliability and test-retest consistency (at an interval of 2 weeks) of the first part of the DuCA were 0.97 and 0.92 respectively. The inter-rater reliability and test-retest consistency of the DuCA total were 0.98 and 0.95 respectively. The correlation coefficients of DuCA-part 1 with ACE-III and MoCA were 0.66 (P < 0.001) and 0.85 (P < 0.001), respectively. The correlation coefficients of DuCA-total with ACE-III and MoCA were 0.78 (P < 0.001) and 0.83 (P < 0.001), respectively. There were weak correlations between years of education, DuCA Part 1 (r = 0.145, P < 0.001), and DuCA total score (r = 0.262, P < 0.001). In the NC group, only 43 participants (4.3%) obtained the maximum DuCA-part 1 score, and a single participant (0.1%) obtained the maximum DuCA-total score, indicating no obvious ceiling effect. Among individuals with MCI or AD, only 14 (1.8%) obtained a DuCA-part 1 score of 0, and none of the participants obtained a DuCA-total score of 0, indicating no obvious floor effect.

Ability of the different scales to discriminate MCI

The discrimination ability was summarized using the AUC. DuCA-part 1 showed a discrimination ability (AUC = 0.87, 95% confidence interval [CI] 0.848–0.883) similar to that of ACE III (AUC = 0.86, 95%CI 0.838–0.874) and MoCA-B (AUC = 0.85, 95%CI 0.830–0.868). DuCA-total showed a higher AUC (0.93, 95%CI: 0.917–0.942) (Table 3).

Table 3 Ability to discriminate MCI from NC

Discrimination ability of DuCA for MCI

To validate the efficacy of DuCA in populations with different levels of education, we stratified the participants according to education. Based on years of education, we divided the participants of the MCI and NC groups into four education levels: ≤6 years of education (n = 108); > 6 years of education and ≤ 99 years (n = 347); > 9 years to ≤ 12 years (n = 569); > 12 years of education (n = 617). For each education level, sex, age, and years of education between the MCI and NC groups were compared, and no significant differences were found. The AUC for discriminating MCI from the NC of DuCA-part 1 and DuCA-total was calculated for each group. At different education levels, the AUC of DuCA-part 1 ranged from 0.83 to 0.84, and that of DuCA-total ranged from 0.89 to 0.94. We provided the recommended cutoff values and corresponding sensitivities and specificities for each education level (Table 4).

Table 4 Discrimination ability of DuCA

Discrimination ability of DuCA for AD

We calculated the ability of the DuCA to discriminate between AD and MCI. The DuCA-Part 1 had an AUC of 0.84. When the cutoff was set to ≤ 3, the sensitivity and specificity were 91.6% and 66.2%, respectively. When the cutoff was set to ≤ 2, the sensitivity and specificity were 53.4% and 86.7%, respectively. The DuCA-total had an AUC of 0.93. When the cutoff was set to ≤ 15, the sensitivity and specificity were 98.5% and 80.0%, respectively. When the cutoff was set to ≤ 13, the sensitivity and specificity were 85.5% and 90.8%, respectively (Table 4).

Discrimination ability for auditory and visual memory impaired MCI

Based on the presence of impaired auditory (AVLT) or visual (BVMT) memory indicators, the MCI group was further divided into MCI with auditory impairment (MCI-A, n = 221, 34.9%), MCI with auditory and visual impairment (MCI-AV, n = 324, 51.2%), and other groups (n = 88, 13.9%).

For MCI-A, DuCA-part 1 (AUC = 0.80, 0.767–0.830) had a similar discrimination ability to ACE III (AUC = 0.82, 0.793–0.850) and MoCA-B (AUC = 0.80, 0.775–0.835) and higher than MMSE (AUC = 0.69, 0.647–0.723). For MCI-AV, DuCA-Part 1 had a similar discrimination ability (AUC = 0.91, 0.888–0.923) to ACE III (AUC = 0.90, 0.882–0.920) and MoCA-B (AUC = 0.91, 0.891–0.926) and higher than MMSE (AUC = 0.80, 0.772–0.828). For other MCI, DuCA-part 1 had a relatively lower discrimination ability (AUC = 0.77, 0.719–0.814) than ACE III (AUC = 0.84, 0.806–0.882), similar to MoCA-B (AUC = 0.79, 0.748–0.835) and higher than MMSE (AUC = 0.66, 0.603–0.723).

Compared to the other tools, DuCA-total had better discrimination ability (AUC for MCI-A:0.89, 0.871–0.913; AUC for MCI-AV:0.96, 0.951–0.970; and AUC for other MCI:0.91, 0.879–0.937) (Table 5).

Table 5 Discrimination ability in MCI subgroups


The DuCA is a two-stage neuropsychological test with screening capabilities similar to those of commonly used cognitive assessment tools for MCI and AD. The concise and flexible features of DuCA allow it to be used as a quick or complete screen, depending on the scenario and purpose. The best and worst cognitive populations can be identified in Part 1, which requires only 3 min. Memory impairment is the earliest typical cognitive impairment in AD. DUCA has a high memory component and is efficient in assessing memory function. DuCA can detect different memory components and help identify abnormalities in the corresponding pathological processes.

Some brief tests that consist of only a few items, such as the Mini-Cog, have shown similar performance in detecting dementia as traditional detection tools [29]. However, most of these brief assessment tools still do not adequately distinguish between MCI and normal cognition [30]. Some brief tools, such as the Rapid Cognitive Screen [31], have also shown a rapid screening ability for MCI [32]. However, other time-consuming assessment tools are required when further assessment of possibly positive individuals is required. Therefore, we aimed to develop a brief tool that included two parts. The first part is used for rapid screening, and the other part is performed when necessary, which, in combination with the first part, can increase the accuracy of the test.

Several screening scales are currently available for large-scale implementation in China. The advantage of the DuCA over these tools is the flexibility of its two-stage approach. The first part of the DuCA is close to the ACE III and MoCA in its ability to discriminate between MCI and NC, but it takes less time. Some tools for evaluating daily abilities, such as ADL and FAQ, are short and easy to use. However, based on the AUC values, the first part of the DuCA was more discriminative for MCI than for ADL or FAQ. When the full version of the DuCA was used, its ability to distinguish MCI from NC was further improved, especially in terms of specificity. By strategically using the two parts of the DuCA, individuals with cognitive impairment can be screened accurately in a relatively short period. Time-saving particularly advantageous for large-scale screening.

Grober et al. experimented with a two-step approach to screen for dementia in primary care with encouraging results [33]. They used the Memory Impairment Screen (four words), animal fluency, and reciting months backward in stage 1, and immediate recall of the free and cued selective reminders test (picture version) in stage 2. In DuCA, the first stage includes semantic executive, delayed recall, and visuospatial ability. The second stage comprises auditory, visual, and semantic executive abilities. Thus, more emphasis has been placed on testing memory functions while retaining language, executive, and visuospatial functions. This is reflected in the fact that DuCA Part 2 contains both auditory and visual memory functions.

According to a meta-analysis, memory tests are the most effective items for screening for MCI in primary care, with delayed recall showing better results than immediate recall [34]. The objects and psychological processes of auditory and visual memory are different, and some studies have suggested that visual memory performance is superior to that of auditory memory [35, 36]. Some researchers believe that auditory and visual memory are distinct memory systems because of different neural circuits [37, 38]. For older adults, visual memory of pictures seems to be more advantageous than that of words [39]. Patients with MCI may have impaired visual memory [40] and tests for visual memory have long been validated to distinguish individuals with MCI from NC individuals [41]. Diminished visual memory is associated with hippocampal atrophy [42]. Hippocampal subregion atrophy is characteristically associated with visual memory impairment in individuals with subjective cognitive decline and MCI [43]. Visual short-term memory performance is closely associated with tau in the entorhinal cortex and inferior temporal lobe. Even in asymptomatic carriers, it is closely associated with amyloid and can therefore be regarded as an early marker of AD pathology [44, 45]. Visual memory evaluation using computerized visual memory assessment with the Cambridge Neuropsychological Test Automated Battery (CANTAB) can distinguish between different types of MCI and predict changes in cognitive status [46]. A visual reproduction test using the Wechsler Memory Scale-Revised can predict the conversion from MCI to AD [47]. Spatial delayed recall, rather than auditory memory items, predicts rapid conversion from cognitively normal to MCI [48]. Therefore, it is necessary to include visual memory detection items in the assessment tool.

The DuCA is a comprehensive multidomain assessment tool. It includes an evaluation of verbal, executive, and visuospatial functions, and a comprehensive memory function assessment. Even though it is brief, it still achieves similar or even better results than commonly used traditional scales. Notably, the performance of the MoCA and MMSE in our MCI cohort was consistent with the results of previous studies [34, 49]. Several studies support our results that multisensory integration is a suitable screening tool for older adults [50, 51]. Using the test your memory for mild cognitive impairment, a brief tool that combines verbal and visual memory assessment, can effectively identify patients with MCI and AD with minimal time and training, and can be combined with other brief assessment tools to further improve accuracy [51].

Education was correlated with baseline cognitive levels in older adults [52, 53]. The performance of DuCA varied among participants with different education levels; therefore, we recommend that different cutoff values based on education level be considered to obtain a more accurate identification.

Our results showed that the DuCA could discriminate between possible AD and MCI. When used for this purpose, the first part of the DuCA had good sensitivity (91.6%) and moderate specificity (66.2%). The DuCA total score significantly improved its specificity (80.0% or 90.8%). Using the first part, some individuals with possible AD may directly be screened; other suspected individuals undergo the second part. This modest reduction in time may be important when a large number of candidates are screened. Therefore, it is considered a good screening tool.

Some participants with MCI only had auditory memory impairment. However, our study showed that using the DuCA did not reduce the ability to discriminate between this population. According to the AUC and 95% CI, the DuCA performed similar to the ACE III and MoCA-B for participants with auditory memory impairment alone and MCI with both auditory and visual memory impairment in terms of their ability to distinguish them from NC. When the DuCA total score was used, the distinguishing ability was significantly improved.


This study had some limitations. The lack of testing for biological markers makes it impossible to explain the correlation between DuCA and pathological changes that lead to cognitive decline. Hence, it was impossible to assess whether DuCA could discriminate between cognitive decline caused by different etiologies. The design that focuses primarily on the assessment of memory function may reduce the sensitivity of DuCA to other etiologies. DuCA may be more appropriate for detecting early stage AD, but has the disadvantage of missing atypical cases with less involvement of memory and executive function. The ability to detect vascular cognitive impairment could not be determined because patients with a history of stroke were not enrolled. The predictive power of DuCA for outcomes could not be evaluated because of the need for more data from longitudinal follow-up. Due to the limitation of the source of participants in this study, the results may differ from the overall situation in a larger region. When using the scale in other areas, especially those with different cultural backgrounds and educational levels, it should be revalidated, and a suitable cutoff should be found first. Our normative cohort that included participants were from the community and a cognitive clinic consisted of individuals with subjective cognitive complaints also. Therefore, there may be subtle differences between the data from our normative group and that from a fully healthy population, which may have resulted in reduced sensitivity.


The DuCA is a two-stage brief assessment tool that is well suited to distinguish adults with cognitive impairment from the NC population and has excellent results for MCI. The first part of the DuCA can be used for rapid screening and is supplemented by the second part for individuals with suspected positive results to increase diagnostic reliability. DuCA can be used for large-scale cognitive screening in primary care settings, saving the time required for cognitive assessment and eliminating the need for extensive training of assessors.

Data availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.


  1. Wang M-Y, Sung H-C, Liu J-Y. Population Aging and its impact on human wellbeing in China. Front Public Health. 2022;10:883566.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020;5:e661–71.

    Article  PubMed  Google Scholar 

  3. Jackson TA, MacLullich AMJ, Gladman JRF, Lord JM, Sheehan B. Diagnostic test accuracy of informant-based tools to diagnose dementia in older hospital patients with delirium: a prospective cohort study. Age Ageing. 2016;45:505–11.

    Article  PubMed  Google Scholar 

  4. Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65:559–64.

    Article  CAS  PubMed  Google Scholar 

  5. Jorm AF. A short form of the Informant Questionnaire on Cognitive decline in the Elderly (IQCODE): development and cross-validation. Psychol Med. 1994;24:145–53.

    Article  CAS  PubMed  Google Scholar 

  6. Chen P, Yu ES, Zhang M, Liu WT, Hill R, Katzman R. ADL dependence and medical conditions in chinese older persons: a population-based survey in Shanghai, China. J Am Geriatr Soc. 1995;43:378–83.

    Article  CAS  PubMed  Google Scholar 

  7. Katzman R, Zhang MY, Ouang-Ya-Qu, Wang ZY, Liu WT, Yu E, et al. A chinese version of the Mini-Mental State examination; impact of illiteracy in a Shanghai dementia survey. J Clin Epidemiol. 1988;41:971–8.

    Article  CAS  PubMed  Google Scholar 

  8. Huang L, Chen K-L, Lin B-Y, Tang L, Zhao Q-H, Lv Y-R, et al. Chinese version of Montreal Cognitive Assessment Basic for discrimination among different severities of Alzheimer’s disease. Neuropsychiatr Dis Treat. 2018;14:2133–40.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Huang Y, Pan F-F, Huang L, Guo Q. The value of clock drawing process Assessment in Screening for mild cognitive impairment and Alzheimer’s dementia. Assessment. 2021;:10731911211053852.

  10. Guo Q, Zhou B, Zhao Q, Wang B, Hong Z. Memory and executive screening (MES): a brief cognitive test for detecting mild cognitive impairment. BMC Neurol. 2012;12:119.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Chiu HFK, Zhong B-L, Leung T, Li SW, Chow P, Tsoh J, et al. Development and validation of a new cognitive screening test: the Hong Kong brief cognitive test (HKBC). Int J Geriatr Psychiatry. 2018;33:994–9.

    Article  PubMed  Google Scholar 

  12. Zhang J, Wang L, Deng X, Fei G, Jin L, Pan X, et al. Five-minute cognitive test as a New Quick Screening of Cognitive Impairment in the Elderly. Aging Dis. 2019;10:1258–69.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ni X, Wu F, Song J, An L, Jiang Q, Bai T, et al. Chinese expert consensus on assessment of cognitive impairment in the elderly. Aging Med (Milton). 2022;5:154–66.

    Article  PubMed  Google Scholar 

  14. Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535–62.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Wang B, Guo Q, Zhao Q, Hong Z. Memory deficits for non-amnestic mild cognitive impairment: memory deficits. J Neuropsychol. 2012;6:232–41.

    Article  CAS  PubMed  Google Scholar 

  16. Li Q, Pan F-F, Huang Q, Lo C-YZ, Xie F, Guo Q. Altered metamemory precedes cognitive impairment in subjective cognitive decline with positive amyloid-beta. Front Aging Neurosci. 2022;14:1046445.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Pan F-F, Wang Y, Huang L, Huang Y, Guo Q-H. Validation of the chinese version of Addenbrooke’s cognitive examination III for detecting mild cognitive impairment. Aging Ment Health. 2022;26:384–91.

    Article  PubMed  Google Scholar 

  18. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:844–52.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Farias ST, Mungas D, Reed BR, Cahn-Weiner D, Jagust W, Baynes K, et al. The measurement of everyday cognition (ECog): scale development and psychometric properties. Neuropsychology. 2008;22:531–44.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323–9.

    Article  CAS  PubMed  Google Scholar 

  21. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Zhao Q, Guo Q, Liang X, Chen M, Zhou Y, Ding D, et al. Auditory verbal learning test is Superior to Rey-Osterrieth Complex figure memory for Predicting mild cognitive impairment to Alzheimer’s Disease. Curr Alzheimer Res. 2015;12:520–6.

    Article  CAS  PubMed  Google Scholar 

  23. Benedict RHB, Schretlen D, Groninger L, Dobraski M, Shpritz B. Revision of the brief Visuospatial Memory Test: studies of normal performance, reliability, and validity. Psychol Assess. 1996;8:145–53.

    Article  Google Scholar 

  24. Zhao Q, Guo Q, Hong Z. Clustering and switching during a semantic verbal fluency test contribute to differential diagnosis of cognitive impairment. Neurosci Bull. 2013;29:75–82.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Knesevich JW, LaBarge E, Edwards D. Predictive value of the Boston naming test in mild senile dementia of the Alzheimer type. Psychiatry Res. 1986;19:155–61.

    Article  CAS  PubMed  Google Scholar 

  26. Zhao Q, Guo Q, Li F, Zhou Y, Wang B, Hong Z. The shape trail test: application of a new variant of the trail making test. PLoS ONE. 2013;8:e57333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Huang L, Chen K, Liu Z, Guo Q. A conceptual Framework for Research on Cognitive Impairment with no dementia in memory clinic. Curr Alzheimer Res. 2020;17:517–25.

    Article  CAS  PubMed  Google Scholar 

  28. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Tsoi KKF, Chan JYC, Hirai HW, Wong SYS, Kwok TCY. Cognitive tests to detect dementia: a systematic review and Meta-analysis. JAMA Intern Med. 2015;175:1450–8.

    Article  PubMed  Google Scholar 

  30. Hemmy LS, Linskens EJ, Silverman PC, Miller MA, Talley KMC, Taylor BC, et al. Brief cognitive tests for distinguishing clinical Alzheimer-Type Dementia from mild cognitive impairment or normal cognition in older adults with suspected cognitive impairment. Ann Intern Med. 2020;172:678–87.

    Article  PubMed  Google Scholar 

  31. Malmstrom TK, Voss VB, Cruz-Oliver DM, Cummings-Vaughn LA, Tumosa N, Grossberg GT, et al. The Rapid Cognitive screen (RCS): a point-of-care screening for dementia and mild cognitive impairment. J Nutr Health Aging. 2015;19:741–4.

    Article  CAS  PubMed  Google Scholar 

  32. Tran J, Nimojan T, Saripella A, Tang-Wai DF, Butris N, Kapoor P, et al. Rapid cognitive assessment tools for screening of mild cognitive impairment in the preoperative setting: a systematic review and meta-analysis. J Clin Anesth. 2022;78:110682.

    Article  PubMed  Google Scholar 

  33. Grober E, Mowrey WB, Ehrlich AR, Mabie P, Hahn S, Lipton RB. Two-stage screening for early dementia in primary care. J Clin Exp Neuropsychol. 2016;38:1038–49.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Tsoi KKF, Chan JYC, Hirai HW, Wong A, Mok VCT, Lam LCW, et al. Recall tests are effective to detect mild cognitive impairment: a systematic review and Meta-analysis of 108 Diagnostic Studies. J Am Med Dir Assoc. 2017;18:807e17–29.

    Article  Google Scholar 

  35. Cohen MA, Horowitz TS, Wolfe JM. Auditory recognition memory is inferior to visual recognition memory. Proc Natl Acad Sci U S A. 2009;106:6008–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Cohen MA, Evans KK, Horowitz TS, Wolfe JM. Auditory and visual memory in musicians and nonmusicians. Psychon Bull Rev. 2011;18:586–91.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Gloede ME, Paulauskas EE, Gregg MK. Experience and information loss in auditory and visual memory. Q J Exp Psychol (Hove). 2017;70:1344–52.

    Article  PubMed  Google Scholar 

  38. Schmid C, Büchel C, Rose M. The neural basis of visual dominance in the context of audio-visual object processing. NeuroImage. 2011;55:304–11.

    Article  PubMed  Google Scholar 

  39. Smith RE, Hunt RR, Dunlap KR. Why do pictures, but not visual words, reduce older adults’ false memories? Psychol Aging. 2015;30:647–55.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Barbeau E, Didic M, Tramoni E, Felician O, Joubert S, Sontheimer A, et al. Evaluation of visual recognition memory in MCI patients. Neurology. 2004;62:1317–22.

    Article  CAS  PubMed  Google Scholar 

  41. Kasai M, Meguro K, Hashimoto R, Ishizaki J, Yamadori A, Mori E. Non-verbal learning is impaired in very mild Alzheimer’s disease (CDR 0.5): normative data from the learning version of the Rey-Osterrieth Complex figure test. Psychiatry Clin Neurosci. 2006;60:139–46.

    Article  PubMed  Google Scholar 

  42. Zammit AR, Ezzati A, Zimmerman ME, Lipton RB, Lipton ML, Katz MJ. Roles of hippocampal subfields in verbal and visual episodic memory. Behav Brain Res. 2017;317:157–62.

    Article  PubMed  Google Scholar 

  43. Huang Y, Huang L, Wang Y, Liu Y, Lo C-YZ, Guo Q. Differential associations of visual memory with hippocampal subfields in subjective cognitive decline and amnestic mild cognitive impairment. BMC Geriatr. 2022;22:153.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Norton DJ, Parra MA, Sperling RA, Baena A, Guzman-Velez E, Jin DS, et al. Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer’s disease. Alzheimers Res Ther. 2020;12:99.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Parra MA, Calia C, Pattan V, Della Sala S. Memory markers in the continuum of the Alzheimer’s clinical syndrome. Alzheimers Res Ther. 2022;14:142.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Campos-Magdaleno M, Leiva D, Pereiro AX, Lojo-Seoane C, Mallo SC, Facal D, et al. Changes in visual memory in mild cognitive impairment: a longitudinal study with CANTAB. Psychol Med. 2021;51:2465–75.

    Article  PubMed  Google Scholar 

  47. Hori T, Sanjo N, Tomita M, Mizusawa H. Visual reproduction on the Wechsler Memory Scale-Revised as a predictor of Alzheimer’s disease in japanese patients with mild cognitive impairments. Dement Geriatr Cogn Disord. 2013;35:165–76.

    Article  PubMed  Google Scholar 

  48. Seo EH, Kim H, Choi KY, Lee KH, Choo IH. Pre-Mild Cognitive Impairment: can Visual Memory Predict who rapidly convert to mild cognitive impairment? Psychiatry Investig. 2018;15:869–75.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Beishon LC, Batterham AP, Quinn TJ, Nelson CP, Panerai RB, Robinson T, et al. Addenbrooke’s cognitive examination III (ACE-III) and mini-ACE for the detection of dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2019;12:CD013282.

    PubMed  Google Scholar 

  50. Murray MM, Eardley AF, Edginton T, Oyekan R, Smyth E, Matusz PJ. Sensory dominance and multisensory integration as screening tools in aging. Sci Rep. 2018;8:8901.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Brown JM, Lansdall CJ, Wiggins J, Dawson KE, Hunter K, Rowe JB, et al. The test your memory for mild cognitive impairment (TYM-MCI). J Neurol Neurosurg Psychiatry. 2017;88:1045–51.

    Article  PubMed  Google Scholar 

  52. van Loenhoud AC, Groot C, Bocancea DI, Barkhof F, Teunissen C, Scheltens P, et al. Association of Education and Intracranial volume with cognitive Trajectories and Mortality Rates across the Alzheimer Disease Continuum. Neurology. 2022;98:e1679–91.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Wilson RS, Yu L, Lamar M, Schneider JA, Boyle PA, Bennett DA. Education and cognitive reserve in old age. Neurology. 2019;92:e1041–50.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


We want to thank Jie-Hua Zhu, Yan-Lu Huang, Yi-Fan Wang, Xian-Qing Xie, and Yun Yang for their help with neuropsychological tests.


This study was funded by the National Natural Science Foundation of China (82171198), Shanghai Municipal Science and Technology Major Project (2018SHZDZX01), Guangdong Provincial Key S&T Program (2018B030336001), and Shanghai Municipal Health Commission (202140042).

Author information

Authors and Affiliations



Conception and design of the study: Liang Cui, Qi-Hao Guo.Acquisition and analysis of data: Liang Cui, Zhen Zhang, Lin Huang, Qinjie Li.Drafting or revising a significant portion of the manuscript or figures: Liang Cui, Zhen Zhang, Yi-Han Guo, Qi-Hao Guo.

Corresponding author

Correspondence to Qi-Hao Guo.

Ethics declarations

Ethics approval and consent to participate

The study was reviewed and approved by the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital. It was performed in accordance with the principles of the Declaration of Helsinki (approval number 2019-041). All participants provided written informed consent to participate in the study.

Consent for publication

Not applicable.

Sponsor’s role

The study sponsors had no role in the design, methods, data collection, analysis, and preparation of the paper.

Conflict of interest

No other disclosure was reported.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1 Table S1 Dual-stage cognitive assessment (DuCA)

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cui, L., Zhang, Z., Huang, L. et al. Dual-stage cognitive assessment: a two-stage screening for cognitive impairment in primary care. BMC Psychiatry 23, 368 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: